We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

AEE:NYSEAmeren Corporation Analysis

Data as of 2026-03-10 - not real-time

$111.41

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

The stock is trading above its 20‑day and 50‑day moving averages, reinforcing a bullish technical backdrop. RSI sits in the upper‑mid range, suggesting limited upside momentum. The MACD histogram has turned negative, indicating a bearish short‑term signal. Volume trends are decreasing, which could dampen price advances toward the identified resistance level. The 30‑day volatility is moderate, while beta is exceptionally low, reflecting defensive characteristics. Fundamentally, earnings per share have risen year‑over‑year, and the forward EPS outlook remains positive. However, revenue has contracted, and free cash flow is negative, raising concerns about cash generation.
The balance sheet shows a high debt‑to‑equity ratio, and total debt exceeds cash by a wide margin. Dividend yield remains attractive for income‑focused investors, and the payout ratio sits near the mid‑range. The board recently increased the quarterly dividend, marking over a decade of consecutive growth. Valuation metrics reveal the market price is well above the DCF‑derived fair value, limiting upside potential. Analyst consensus is a buy, but the median target price only offers modest upside. Overall, the stock presents a mixed picture of solid income but stretched valuation. Investors should weigh the defensive sector attributes against the valuation premium and debt profile.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • MACD bearish crossover
  • approaching resistance level
  • decreasing volume

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • price above key moving averages
  • attractive dividend yield
  • stable earnings growth

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • significant overvaluation versus DCF fair value
  • high debt load
  • negative free cash flow

Key Metrics & Analysis

Financial Health

Revenue Growth-8.80%
Profit Margin17.19%
P/E Ratio20.8
ROE11.34%
ROA3.05%
Debt/Equity147.13
P/B Ratio2.3
Op. Cash Flow$3.4B
Free Cash Flow$-1484375040
Industry P/E20.9

Technical Analysis

TrendBullish
RSI59.8
Support$104.30
Resistance$113.64
MA 20$110.69
MA 50$105.63
MA 200$101.62
MACDBearish
VolumeDecreasing
Fear & Greed Index80.32

Valuation

Fair Value$45.41
Target Price$115.69
Upside/Downside3.84%
GradeOvervalued
TypeValue
Dividend Yield2.70%

Risk Assessment

Beta0.19
Volatility16.46%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.